TY - JOUR
T1 - Alterations in the Plasma Levels of Specific Choline Phospholipids in Alzheimer's Disease Mimic Accelerated Aging
AU - Dorninger, Fabian
AU - Moser, Ann B.
AU - Kou, Jianqiu
AU - Wiesinger, Christoph
AU - Forss-Petter, Sonja
AU - Gleiss, Andreas
AU - Hinterberger, Margareta
AU - Jungwirth, Susanne
AU - Fischer, Peter
AU - Berger, Johannes
N1 - Funding Information:
The authors thank Paul Watkins for critically reading the manuscript. The present study was funded by the Austrian Science Fund (FWF; P 24843-B24, P 21950-B20 and I2738-B26 to JB). The Vienna Trans-danube Aging (VITA) study was supported by the Ludwig Boltzmann Society, Vienna (Austria), and was carried out at the Ludwig Boltzmann Institute of Aging Research at the Danube Hospital, Vienna, Austria. The funders did not participate in study design, data collection or generation of the manuscript.
Publisher Copyright:
© 2018 - IOS Press and the authors. All rights reserved.
PY - 2018
Y1 - 2018
N2 - Alzheimer's disease (AD) is the most common neurodegenerative disease and of continuously rising prevalence. The identification of easy-to-measure biomarkers capable to assist in the prediction and early diagnosis of AD is currently a main research goal. Lipid metabolites in peripheral blood of human patients have recently gained major attention in this respect. Here, we analyzed plasma of 174 participants (not demented at baseline; mean age: 75.70±0.44 years) of the Vienna Transdanube Aging (VITA) study, a longitudinal, population-based birth cohort study, at baseline and after 90 months or at diagnosis of probable AD. We determined the levels of specific choline phospholipids, some of which have been suggested as potential biomarkers for the prediction of AD. Our results show that during normal aging the levels of lysophosphatidylcholine, choline plasmalogen, and lyso-platelet activating factor increase significantly. Notably, we observed similar but more pronounced changes in the group that developed probable AD. Thus, our results imply that, in terms of choline-containing plasma phospholipids, the conversion to AD mimics an accelerated aging process. We conclude that age, even in the comparatively short time frame between 75 and 82.5 years, is a crucial factor in the quest for plasma lipid biomarkers for AD that must be carefully considered in future studies and trials.
AB - Alzheimer's disease (AD) is the most common neurodegenerative disease and of continuously rising prevalence. The identification of easy-to-measure biomarkers capable to assist in the prediction and early diagnosis of AD is currently a main research goal. Lipid metabolites in peripheral blood of human patients have recently gained major attention in this respect. Here, we analyzed plasma of 174 participants (not demented at baseline; mean age: 75.70±0.44 years) of the Vienna Transdanube Aging (VITA) study, a longitudinal, population-based birth cohort study, at baseline and after 90 months or at diagnosis of probable AD. We determined the levels of specific choline phospholipids, some of which have been suggested as potential biomarkers for the prediction of AD. Our results show that during normal aging the levels of lysophosphatidylcholine, choline plasmalogen, and lyso-platelet activating factor increase significantly. Notably, we observed similar but more pronounced changes in the group that developed probable AD. Thus, our results imply that, in terms of choline-containing plasma phospholipids, the conversion to AD mimics an accelerated aging process. We conclude that age, even in the comparatively short time frame between 75 and 82.5 years, is a crucial factor in the quest for plasma lipid biomarkers for AD that must be carefully considered in future studies and trials.
KW - Biomarkers
KW - blood
KW - lyso-PAF
KW - lysophosphatidylcholines
KW - lysophospholipids
KW - mass spectrometry
KW - plasmalogens
UR - http://www.scopus.com/inward/record.url?scp=85043598936&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85043598936&partnerID=8YFLogxK
U2 - 10.3233/JAD-171036
DO - 10.3233/JAD-171036
M3 - Article
C2 - 29480199
AN - SCOPUS:85043598936
SN - 1387-2877
VL - 62
SP - 841
EP - 854
JO - Journal of Alzheimer's Disease
JF - Journal of Alzheimer's Disease
IS - 2
ER -